Outlook Therapeutics, Inc.(OTLK),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

OTLK Outlook Therapeutics, Inc.

Post-Mkt 04-10 16:57:12 EDT

0.2490

+0.0268

+12.06%

盘后0.2405

-0.0085-3.41%

16:53 EDT

High0.2500	Low0.2230	Vol2.12M
Open0.2300	D1 Closing0.2222	Amplitude12.15%
Mkt Cap26.15M	Tradable Cap22.23M	Total Shares105.00M
T/O489.28K	T/O Rate2.37%	Tradable Shares89.28M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"OTLK","market":"US","secType":"STK","nameCN":"Outlook Therapeutics, Inc.","latestPrice":0.249,"timestamp":1775851200000,"preClose":0.2222,"halted":0,"volume":2117100,"hourTrading":{"tag":"盘后","latestPrice":0.2405,"preClose":0.249,"latestTime":"16:53 EDT","volume":10202,"amount":2458.84033504,"timestamp":1775854392835,"change":-0.0085,"changeRate":-0.034137,"amplitude":0.065462},"delay":0,"changeRate":0.12061206120612056,"floatShares":89280200,"shares":105000000,"eps":-2.89,"marketStatus":"Post-Mkt","change":0.0268,"latestTime":"04-10 16:57:12 EDT","open":0.23,"high":0.25,"low":0.223,"amount":489276.883752,"amplitude":0.121512,"askPrice":0.2406,"askSize":70,"bidPrice":0.226,"bidSize":1200,"shortable":0,"etf":0,"ttmEps":-2.89,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1775865600000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":0.2222,"preHourTrading":{"tag":"盘前","latestPrice":0.2263,"preClose":0.2222,"latestTime":"09:27 EDT","volume":72489,"amount":16478.893199730002,"timestamp":1775827628357,"change":0.0041,"changeRate":0.018452,"amplitude":0.043204},"postHourTrading":{"tag":"盘后","latestPrice":0.2405,"preClose":0.249,"latestTime":"16:53 EDT","volume":10202,"amount":2458.84033504,"timestamp":1775854392835,"change":-0.0085,"changeRate":-0.034137,"amplitude":0.065462},"volumeRatio":0.300749,"impliedVol":1.3233,"impliedVolPercentile":0.424},"requestUrl":"/m/hq/s/OTLK/wiki","defaultTab":"wiki","newsList":[{"id":"2625696863","title":"Outlook Therapeutics Files FDA Resolution Request After Rejection For Vision Loss Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2625696863","media":"Benzinga_recent_news","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625696863?lang=en_us&edition=fundamental","pubTime":"2026-04-08 02:11","pubTimestamp":1775585460,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics files FDA dispute on ONS-5010 after CRL citing effectiveness concerns; meeting with agency official set for April 2026.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/04/07/FDA-Warns-Check-Can-Codes.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/04/07/FDA-Warns-Check-Can-Codes.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/fda/26/04/51688863/outlook-therapeutics-files-fda-resolution-request-after-rejection-for-vision-loss-drug","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/fda/26/04/51688863/outlook-therapeutics-files-fda-resolution-request-after-rejection-for-vision-loss-drug","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4007","IE00BFMHRM44.USD","LABU","LU1815336091.USD","BK4121","BK4139","FDRR","LENZ","BK4539","CRL","LU0390134368.USD","BK4588","BK4585","LU0757428866.USD","OTLK","LU0029874061.USD","BK4530","LU0128526141.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625955505","title":"Outlook Therapeutics submits formal dispute resolution request to FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2625955505","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625955505?lang=en_us&edition=fundamental","pubTime":"2026-04-07 21:19","pubTimestamp":1775567943,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics (OTLK) announced that it submitted a formal dispute resolution request to the FDA as a follow-up to its recent Type A meeting ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/outlook-therapeutics-submits-formal-dispute-resolution-request-to-fda-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/outlook-therapeutics-submits-formal-dispute-resolution-request-to-fda-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","LABU","BK4585","BK4588","LENZ","OTLK","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625953298","title":"BUZZ-Outlook Therapeutics rises as FDA agrees to review eye drug decision","url":"https://stock-news.laohu8.com/highlight/detail?id=2625953298","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625953298?lang=en_us&edition=fundamental","pubTime":"2026-04-07 21:01","pubTimestamp":1775566871,"startTime":"0","endTime":"0","summary":"BUZZ-Outlook Therapeutics rises as FDA agrees to review eye drug decision** Shares of drugmaker Outlook Therapeutics OTLK.O rise about 10% to $0.22 premarket** Co says it has asked the U.S. FDA to reconsider its decision not to approve its experimental eye drug ons-5010/lytenava** Co says FDA accepted a formal dispute resolution request and will meet the company later this month** Drug targets wet age-related macular degeneration, a common eye disease that causes vision loss due to leaking blood vessels in the retina** Co says data from NORSE TWO and NORSE EIGHT studies show the drug is safe and effective, with no safety concerns flagged by the FDA** Adds the drug is already approved in Europe and the UK, where commercial launches have begun** As of last close, stock down ~87% YTD  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nL4N40Q0X3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625953674","title":"BRIEF-Outlook Therapeutics Announces Formal Dispute Resolution Request For Ons-5010/Lytenava™ (Bevacizumab-Vikg) Accepted By FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2625953674","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625953674?lang=en_us&edition=fundamental","pubTime":"2026-04-07 20:55","pubTimestamp":1775566531,"startTime":"0","endTime":"0","summary":"BRIEF-Outlook Therapeutics Announces Formal Dispute Resolution Request For Ons-5010/Lytenava (Bevacizumab-Vikg) Accepted By FDAApril 7 (Reuters) - Outlook Therapeutics Inc OTLK.O:OUTLOOK THERAPEUTICS ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nTUA3BS9QP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622004992","title":"Outlook Therapeutics closes $5.0 million public offering; warrants target up to $5.0 million additional proceeds","url":"https://stock-news.laohu8.com/highlight/detail?id=2622004992","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622004992?lang=en_us&edition=fundamental","pubTime":"2026-03-26 04:06","pubTimestamp":1774469166,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics closed a public offering of 20,000,000 common shares with warrants to buy up to 20,000,000 additional common shares.The combined offering price was USD 0.25 per share and accompanying warrant.Gross proceeds were USD 5.0 million, before fees and expenses.Each warrant has an exercise price of USD 0.25 and expires five years after issuance.Net proceeds are intended primarily for working capital and general corporate purposes.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nNDL7P6TCt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLK","BK4588","IE00B64PRP62.GBP","BK4112","BK4585","IE00BN0W2V16.EUR","SG9999014013.SGD","LU2210149790.SGD","IE00BKPKM429.USD","IE00BN0W2W23.USD","IE00BN0W2T93.GBP","IE00B3QW5Z07.USD","LU2210150020.SGD","NDAQ","SG9999014039.USD","SG9999014005.SGD","LU0314104364.USD","IE00BGHQF748.EUR","BK4139","LU2095319765.USD","SG9999014021.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622004617","title":"Press Release: Outlook Therapeutics Announces Closing of $5.0 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2622004617","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622004617?lang=en_us&edition=fundamental","pubTime":"2026-03-26 04:05","pubTimestamp":1774469100,"startTime":"0","endTime":"0","summary":"ISELIN, N.J., March 25, 2026  -- Outlook Therapeutics, Inc. , a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced the closing of its previously announced public offering of 20,000,000 shares of its common stock and accompanying warrants to purchase up to an aggregate of 20,000,000 shares of common stock. Each share of common stock and accompanying common warrant were sold together at a combined public offering price of $0.25. Each common warrant has an exercise price of $0.25 per share, is exercisable immediately and expires five years from the date of issuance.The aggregate gross proceeds of the offering were $5.0 million, before deducting placement agent fees and other offering expenses. The potential additional gross proceeds to Outlook Therapeutics from the common warrants, if fully exercised on a cash basis, will be approximately $5.0 million. No assurance can be given that any of the common wa","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TM","BK4099","BK4539","LENZ","BK4139","03160","BK4604","BK4555","OTLK","BK4007","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622097434","title":"Outlook Therapeutics Shares Drop After $5 Million Public Offering Priced","url":"https://stock-news.laohu8.com/highlight/detail?id=2622097434","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622097434?lang=en_us&edition=fundamental","pubTime":"2026-03-25 02:32","pubTimestamp":1774377154,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics  shares fell 39% in Tuesday trading after the company priced a public offering of 20 million shares at $0.25 each for gross proceeds of $5 million.Intraday volume topped 22.9 million shares versus the daily average of 5.33 million.Price: 0.19, Change: -0.13, Percent Change: -39.59","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OTLK","LENZ","BK4007","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621306626","title":"Outlook Therapeutics prices USD 5 million public offering at USD 0.25 per share with warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2621306626","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621306626?lang=en_us&edition=fundamental","pubTime":"2026-03-24 19:01","pubTimestamp":1774350085,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics priced a public offering of 20,000,000 common shares with warrants to buy up to 20,000,000 additional shares.The combined offering price is USD 0.25 per share and accompanying warrant, for expected gross proceeds of USD 5.0 million.Warrants have an exercise price of USD 0.25 per share and expire five years after issuance.Closing is expected on or about March 25, 2026, subject to customary conditions.Net proceeds are intended primarily for working capital and general corporate purposes.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nNDL2jWWLy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","IE00BGHQF748.EUR","BK4112","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP","SG9999014021.USD","BK4585","BK4588","LU2210149790.SGD","IE00B3QW5Z07.USD","SG9999014013.SGD","OTLK","LU2210150020.SGD","SG9999014005.SGD","IE00B64PRP62.GBP","IE00BN0W2W23.USD","LU0314104364.USD","SG9999014039.USD","BK4139","IE00BKPKM429.USD","LU2095319765.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621664330","title":"Outlook Therapeutics Announces Pricing of $5.0 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2621664330","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621664330?lang=en_us&edition=fundamental","pubTime":"2026-03-24 19:00","pubTimestamp":1774350005,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nTUA5DPS1D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","OTLK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621871430","title":"BRIEF-Outlook Therapeutics Announces Proposed Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2621871430","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621871430?lang=en_us&edition=fundamental","pubTime":"2026-03-24 05:31","pubTimestamp":1774301488,"startTime":"0","endTime":"0","summary":"BRIEF-Outlook Therapeutics Announces Proposed Public OfferingMarch 23 (Reuters) - Outlook Therapeutics Inc OTLK.O:OUTLOOK THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERINGSource text: ID:nGNX5pQbgxFurther company coverage: OTLK.O ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nTUA3BFNT2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621871150","title":"Outlook Therapeutics launches best-efforts public offering of common stock and warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2621871150","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621871150?lang=en_us&edition=fundamental","pubTime":"2026-03-24 05:30","pubTimestamp":1774301423,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics commenced a best-efforts public offering of common stock or pre-funded warrants, along with accompanying warrants exercisable for common stock.H.C. Wainwright is acting as the exclusive placement agent for the offering.Net proceeds are intended to be used primarily for working capital and general corporate purposes.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDL2Mr1yk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","BK4112","IE00BGHQF748.EUR","SG9999014005.SGD","BK4588","IE00BKPKM429.USD","BK4139","SG9999014021.USD","OTLK","NDAQ","IE00B3QW5Z07.USD","LU0314104364.USD","IE00BN0W2V16.EUR","IE00BN0W2W23.USD","LU2095319765.USD","IE00BN0W2T93.GBP","SG9999014039.USD","LU2210150020.SGD","BK4585","SG9999014013.SGD","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621808768","title":"Outlook Therapeutics Launches LYTENAVA in Germany and the UK","url":"https://stock-news.laohu8.com/highlight/detail?id=2621808768","media":"Reuters","labels":["shareholding","productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621808768?lang=en_us&edition=fundamental","pubTime":"2026-03-24 05:19","pubTimestamp":1774300793,"startTime":"0","endTime":"0","summary":"Outlook said LYTENAVA  is approved in the EU and the UK for wet age-related macular degeneration, positioning the company to compete in a market where off-label bevacizumab is widely used.The company reported it launched directly in Germany and the UK in June 2025 and is planning additional EU launches either directly or through licensing partners.Outlook estimated the EU anti-VEGF retina market at about USD 3.6 billion and the US anti-VEGF retina market at about USD 8.5 billion.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Outlook Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDLszVrK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OTLK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619686764","title":"Outlook Therapeutics Inc - Extends Maturity Date of Existing Convertible Note to December 31, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2619686764","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619686764?lang=en_us&edition=fundamental","pubTime":"2026-03-16 20:05","pubTimestamp":1773662700,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nTUA1BNLFM:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OTLK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619468937","title":"Outlook Therapeutics Inc - Enters $18.4 Mln New Note, Expects $17 Mln Net Proceeds","url":"https://stock-news.laohu8.com/highlight/detail?id=2619468937","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619468937?lang=en_us&edition=fundamental","pubTime":"2026-03-16 20:05","pubTimestamp":1773662700,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nTUA1BNLFM:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OTLK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619468907","title":"Outlook Therapeutics Inc - Lender Confirms Existing Note Is Not in Default","url":"https://stock-news.laohu8.com/highlight/detail?id=2619468907","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619468907?lang=en_us&edition=fundamental","pubTime":"2026-03-16 20:05","pubTimestamp":1773662700,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nTUA1BNLFM:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OTLK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619118468","title":"Outlook Therapeutics Inc - Proceeds From New Note to Pay Down Existing Note, $10.8 Mln Principal and Interest Remaining on Existing Note","url":"https://stock-news.laohu8.com/highlight/detail?id=2619118468","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619118468?lang=en_us&edition=fundamental","pubTime":"2026-03-16 20:05","pubTimestamp":1773662700,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nTUA1BNLFM:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OTLK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619450024","title":"Press Release: Outlook Therapeutics Announces New $18.4 Million Non-Convertible Note Financing and Amendment to Existing Convertible Note","url":"https://stock-news.laohu8.com/highlight/detail?id=2619450024","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619450024?lang=en_us&edition=fundamental","pubTime":"2026-03-16 20:05","pubTimestamp":1773662700,"startTime":"0","endTime":"0","summary":"ISELIN, N.J., March 16, 2026  -- Outlook Therapeutics, Inc. , a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced an amendment to its existing convertible note with Avondale Capital, LLC  and the issuance of a new non-convertible, unsecured note with Atlas Sciences, LLC .Under the amendment to the Existing Note, the maturity date of the Existing Note has been extended to December 31, 2026, with no other changes to the terms. The lender has confirmed that the Existing Note is not in default.In addition, Outlook Therapeutics entered into the $18.4 million New Note. The Company expects to receive $17 million in net proceeds, after original issue discount. Proceeds from the New Note will be used to pay down a portion of the Existing Note, reducing the balance and leaving approximately $10.8 million of principal and interest remaining on the Existing Note.The New Note bears interest at a rate equal to th","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMYY","BK4566","BK4539","BK4007","AMDY","AMDD","AMDG","LU0390134368.USD","LU0719512351.SGD","AMDU","BK4512","LU0082616367.USD","03160","LU1923623000.USD","AMDW","LU1988902786.USD","TM","LU1951198990.SGD","LU0889565833.HKD","LU2931357623.SGD","LU1242518931.SGD","DAMD","AMUU","BK4573","LU0056508442.USD","LU1880398471.USD","LENZ","LU2355687059.USD","LU1989764664.SGD","BK4554","BK4604","BK4612","LU2458330169.SGD","LU2458330243.SGD","LU1316542783.SGD","OTLK","BK4543","BK4141","BK4529","LU1064131342.USD","LU2098885051.SGD","BK4534","LU0109392836.USD","IE00BMPRXN33.USD","LU1880398554.USD","LU1951200564.SGD","AMDL","BK4588","LU0823421333.USD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2618976218","title":"Outlook Therapeutics director Julia A. Haller to step down effective March 10, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2618976218","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618976218?lang=en_us&edition=fundamental","pubTime":"2026-03-12 05:17","pubTimestamp":1773263840,"startTime":"0","endTime":"0","summary":"Julia Haller will step down from the board of Outlook Therapeutics effective March 10, 2026. Haller cited time constraints after taking on new responsibilities as CEO at Wills Eye Hospital.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Outlook Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 11, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nNDL1FhDg2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OTLK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617995571","title":"Outlook Therapeutics provides update following FDA meeting on ONS-5010","url":"https://stock-news.laohu8.com/highlight/detail?id=2617995571","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617995571?lang=en_us&edition=fundamental","pubTime":"2026-03-06 05:55","pubTimestamp":1772747720,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics (OTLK) provided an update following its recent Type A meeting with the FDA to discuss the December 30, 2025 complete response ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/outlook-therapeutics-provides-update-following-fda-meeting-on-ons-5010-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/outlook-therapeutics-provides-update-following-fda-meeting-on-ons-5010-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","LENZ","BK4139","OTLK","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617761925","title":"Outlook Therapeutics Updates on FDA Type A Meeting for ONS-5010/LYTENAVA BLA","url":"https://stock-news.laohu8.com/highlight/detail?id=2617761925","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617761925?lang=en_us&edition=fundamental","pubTime":"2026-03-06 05:15","pubTimestamp":1772745336,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics said it held a Type A meeting with the U.S. FDA to discuss the December 30, 2025 Complete Response Letter for its Biologics License Application for ONS-5010/LYTENAVA , focused on the FDA’s outstanding issue regarding substantial evidence of effectiveness and potential paths forward. The company said NORSE TWO, a randomized, double-masked, active-controlled Phase 3 trial, met its primary and key secondary endpoints and showed clinically meaningful and statistically significant improvements in visual acuity, and that NORSE EIGHT and other BLA information provided confirmatory evidence of efficacy and safety, including functional and pharmacodynamic evidence consistent with an anti-VEGF mechanism of action. Outlook Therapeutics added that no safety concerns were identified by the FDA and that it is evaluating regulatory options while continuing discussions with the agency.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nNDL1PpgtG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","LU2095319765.USD","LU2210149790.SGD","IE00BKPKM429.USD","BK4588","SG9999014021.USD","BK4585","IE00B64PRP62.GBP","SG9999014039.USD","LU0314104364.USD","BK4139","IE00B3QW5Z07.USD","LU2210150020.SGD","SG9999014005.SGD","BK4112","OTLK","NDAQ","SG9999014013.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.outlooktherapeutics.com","stockEarnings":[{"period":"1week","weight":0.0146},{"period":"1month","weight":-0.5007},{"period":"3month","weight":-0.6234},{"period":"6month","weight":-0.8148},{"period":"1year","weight":-0.8148},{"period":"ytd","weight":-0.8594}],"compareEarnings":[{"period":"1week","weight":0.0367},{"period":"1month","weight":0.004},{"period":"3month","weight":-0.0204},{"period":"6month","weight":0.0412},{"period":"1year","weight":0.2393},{"period":"ytd","weight":-0.0029}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.033268},{"month":2,"riseRate":0.4,"avgChangeRate":0.1402},{"month":3,"riseRate":0.3,"avgChangeRate":-0.095662},{"month":4,"riseRate":0.5,"avgChangeRate":-0.084209},{"month":5,"riseRate":0.666667,"avgChangeRate":0.154179},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.046947},{"month":7,"riseRate":0.6,"avgChangeRate":0.042124},{"month":8,"riseRate":0.3,"avgChangeRate":-0.178581},{"month":9,"riseRate":0.5,"avgChangeRate":0.048784},{"month":10,"riseRate":0.5,"avgChangeRate":0.176993},{"month":11,"riseRate":0.2,"avgChangeRate":-0.102562},{"month":12,"riseRate":0.3,"avgChangeRate":-0.107149}],"exchange":"NASDAQ","name":"Outlook Therapeutics, Inc.","nameEN":"Outlook Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Outlook Therapeutics, Inc.(OTLK),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Outlook Therapeutics, Inc.(OTLK) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Outlook Therapeutics, Inc.,OTLK,Outlook Therapeutics, Inc.股票,Outlook Therapeutics, Inc.股票老虎,Outlook Therapeutics, Inc.股票老虎国际,Outlook Therapeutics, Inc.行情,Outlook Therapeutics, Inc.股票行情,Outlook Therapeutics, Inc.股价,Outlook Therapeutics, Inc.股市,Outlook Therapeutics, Inc.股票价格,Outlook Therapeutics, Inc.股票交易,Outlook Therapeutics, Inc.股票购买,Outlook Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Outlook Therapeutics, Inc.(OTLK),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Outlook Therapeutics, Inc.(OTLK) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}